Pine River Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Pine River Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-3,100	Closed	-$386K	–	684
2015 Q1	$386K	Buy	+3,100	New	+$328K	﹤0.01%	535

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Pine River Capital Management's BMRN Position: Q2 2015 in Review

Pine River Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2015, closing a stake of 3,100 shares — an estimated $386K sold.

Pine River Capital Management first reported a position in BMRN in Q1 2015 and held it in 1 quarter. The position peaked at $386K in Q1 2015. 391 funds tracked by Wall St. Rank hold BMRN as of Q2 2015.

Pine River Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Pine River Capital Management sold 3,100 BioMarin Pharmaceuticals shares in Q2 2015, an estimated $386K.
Pine River Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 1 quarter.
Pine River Capital Management's BioMarin Pharmaceuticals position peaked at $386K in Q1 2015.
391 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2015.

Based on Pine River Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.